Significant progress has been made in the last few years in the clinical diagnosis of AD, such as the development of sensitive Single Molecular Array (Simoa) assays for site-specific phospho-tau epitope detection (such as p-tau181, p-tau217, and p-tau231) to differentiate AD from non-AD with brain tissues, CSF and blood samples (Rissin et al., 2010; Blennow et al., 2015; Janelidze et al., 2020; Ashton et al., 2021, 2022; Thijssen et al., 2021). Here, MAPT is linked to Alzheimer disease.